Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Wellington Management Group LLP

Wellington Management Group LLP cut its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 0.9% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,772,042 shares of the pharmaceutical company’s stock after selling 41,344 shares during the quarter. Wellington Management Group LLP owned 1.88% of Vertex Pharmaceuticals worth $1,868,923,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Leuthold Group LLC acquired a new stake in Vertex Pharmaceuticals during the 3rd quarter valued at approximately $5,030,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its position in shares of Vertex Pharmaceuticals by 3.8% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 544,978 shares of the pharmaceutical company’s stock valued at $213,435,000 after purchasing an additional 20,053 shares in the last quarter. Advisory Resource Group purchased a new position in shares of Vertex Pharmaceuticals during the 3rd quarter valued at approximately $1,286,000. Generali Asset Management SPA SGR boosted its stake in shares of Vertex Pharmaceuticals by 41.8% during the 3rd quarter. Generali Asset Management SPA SGR now owns 23,569 shares of the pharmaceutical company’s stock valued at $9,231,000 after buying an additional 6,942 shares during the last quarter. Finally, Welch & Forbes LLC grew its position in shares of Vertex Pharmaceuticals by 1.4% during the third quarter. Welch & Forbes LLC now owns 220,346 shares of the pharmaceutical company’s stock worth $86,296,000 after buying an additional 3,102 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Duncan Mckechnie sold 4,910 shares of Vertex Pharmaceuticals stock in a transaction dated Wednesday, February 25th. The shares were sold at an average price of $487.65, for a total value of $2,394,361.50. Following the completion of the transaction, the executive vice president directly owned 17,559 shares of the company’s stock, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Ourania Tatsis sold 4,500 shares of the business’s stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $474.99, for a total transaction of $2,137,455.00. Following the sale, the executive vice president directly owned 42,293 shares of the company’s stock, valued at approximately $20,088,752.07. This represents a 9.62% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 91,156 shares of company stock worth $42,845,497. Company insiders own 0.20% of the company’s stock.

Analyst Ratings Changes

VRTX has been the subject of a number of research analyst reports. Morgan Stanley lifted their price target on shares of Vertex Pharmaceuticals from $570.00 to $596.00 and gave the stock an “overweight” rating in a research note on Tuesday. Truist Financial increased their price objective on shares of Vertex Pharmaceuticals from $490.00 to $525.00 and gave the company a “buy” rating in a research note on Wednesday. Sanford C. Bernstein reissued an “outperform” rating and set a $577.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Stifel Nicolaus boosted their target price on shares of Vertex Pharmaceuticals from $445.00 to $466.00 and gave the stock a “hold” rating in a research report on Friday, February 13th. Finally, Jefferies Financial Group assumed coverage on shares of Vertex Pharmaceuticals in a research report on Tuesday. They set a “buy” rating and a $580.00 price target on the stock. Twenty-three research analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and an average price target of $553.36.

Vertex Pharmaceuticals Trading Down 1.8%

VRTX stock opened at $469.34 on Friday. The stock’s 50 day simple moving average is $470.03 and its 200 day simple moving average is $437.76. Vertex Pharmaceuticals Incorporated has a 12-month low of $362.50 and a 12-month high of $519.68. The firm has a market cap of $119.23 billion, a P/E ratio of 30.62, a P/E/G ratio of 2.04 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings data on Thursday, February 12th. The pharmaceutical company reported $5.03 EPS for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business had revenue of $3.19 billion during the quarter, compared to analyst estimates of $3.18 billion. During the same period in the prior year, the firm earned $3.98 EPS. The business’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, research analysts forecast that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current fiscal year.

Trending Headlines about Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Several major analysts raised coverage and targets for VRTX, boosting bullish sentiment and shorter-term buying interest. Oppenheimer Raises Vertex Pharmaceuticals (NASDAQ:VRTX) Price Target to $600.00
• Positive Sentiment: Analyst upgrades translated into intraday strength earlier in the week (shares traded notably higher on upgrade headlines), signaling renewed investor appetite. Vertex Pharmaceuticals (NASDAQ:VRTX) Trading 9.9% Higher on Analyst Upgrade
• Positive Sentiment: New research coverage from Jefferies adds another channel for institutional visibility and could support longer-term demand. Vertex Pharmaceuticals (NASDAQ:VRTX) Research Coverage Started at Jefferies Financial Group
• Positive Sentiment: Retail and media interest has picked up — headlines highlighting a recent ~8% jump are drawing attention from momentum traders. This helps explain recent volume spikes and short-term volatility. This Stock Just Jumped By 8%: Is It Too Late to Buy?
• Neutral Sentiment: “Trending stock” write-ups from Zacks/Yahoo summarize catalysts and risks for new readers; useful for context but unlikely to move price by themselves. Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: Analyses that list reasons to watch VRTX (growth from cystic fibrosis and extending franchises) and one caution help frame investor decisions but don’t introduce a new catalyst. 2 Reasons to Watch VRTX and 1 to Stay Cautious
• Neutral Sentiment: Long-term performance pieces and market-focus coverage provide background on investor returns and index attention; helpful for positioning but not immediate drivers. If You Invested $1000 In Vertex Pharmaceuticals Stock 20 Years Ago…
• Negative Sentiment: Despite the upgrades, the stock has retraced from the immediate highs — recent intraday declines and a prior small earnings EPS miss (Feb quarter EPS slightly below consensus) leave some investors taking profits. Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.